Gutiérrez-Suárez Raul, Ruperto Nicolino, Gastaldi Roberto, Pistorio Angela, Felici Enrico, Burgos-Vargas Rubén, Martini Alberto, Ravelli Angelo
IRCCS G. Gaslini, Genoa, Italy.
Arthritis Rheum. 2006 Sep;54(9):2989-96. doi: 10.1002/art.22048.
To devise a modified version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) for use in children and adolescents with systemic lupus erythematosus (SLE), based on the frequency and distribution of damage in patients with juvenile-onset SLE and the sources of damage that are most suitable for inclusion in a pediatric damage index.
In this cross-sectional study, damage was assessed through the SDI. Clinical assessments included evaluation of growth failure and delayed puberty, which were believed to be important sources of damage that are not incorporated in the SDI but should be included in a pediatric version of the instrument.
A total of 1,015 patients with juvenile-onset SLE in 39 countries were enrolled in the study. Of these, 405 patients (39.9%) had an SDI score of > or =1 (mean +/- SD score 0.8 +/- 1.4). Renal damage (13%), neuropsychiatric damage (10.7%), and musculoskeletal damage (10.7%) were observed most frequently, followed by ocular damage (8.2%) and skin damage (7.6%). Growth failure and delayed puberty were recorded in 15.3% and 11.3% of patients, respectively. A pediatric version of the SDI was devised, with inclusion of growth failure and delayed puberty as new domains.
We propose a modified version of the SDI for use in patients with juvenile-onset SLE. This new instrument warrants prospective validation in other populations of patients seen in different clinical or research settings.
基于青少年起病的系统性红斑狼疮(SLE)患者损伤的频率和分布情况以及最适合纳入儿科损伤指数的损伤来源,设计系统性红斑狼疮国际协作临床/美国风湿病学会损伤指数(SDI)的改良版,用于儿童和青少年SLE患者。
在这项横断面研究中,通过SDI评估损伤情况。临床评估包括生长发育迟缓及青春期延迟的评估,这些被认为是重要的损伤来源,未纳入SDI但应包含在该工具的儿科版本中。
来自39个国家的1015例青少年起病的SLE患者纳入研究。其中,405例患者(39.9%)的SDI评分≥1(平均±标准差评分0.8±1.4)。最常观察到的损伤为肾脏损伤(13%)、神经精神损伤(10.7%)和肌肉骨骼损伤(10.7%),其次是眼部损伤(8.2%)和皮肤损伤(7.6%)。分别有15.3%和11.3%的患者记录有生长发育迟缓和青春期延迟。设计了SDI的儿科版本,将生长发育迟缓和青春期延迟纳入新的领域。
我们提出了一种用于青少年起病的SLE患者的SDI改良版。这一新工具需要在不同临床或研究环境中观察的其他患者群体中进行前瞻性验证。